Post by FDA

Agitation is one of the most difficult and distressing symptoms for Alzheimer's patients and their caregivers — a new FDA-approved option offers hope. Auvelity has been approved to treat agitation associated with Alzheimer's disease dementia in adults, making it the first non-antipsychotic drug approved for this condition. This is a significant step forward for patients and families navigating the challenges of Alzheimer's disease. Learn more: https://lnkd.in/eVt4dQjP